Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells
about
The detection, treatment, and biology of epithelial ovarian cancerImmunologic aspect of ovarian cancer and p53 as tumor antigen.Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor MicroenvironmentNKG2D ligands as therapeutic targetsTumor infiltrating lymphocytes in ovarian cancerAntigen-specific immunotherapy of cervical and ovarian cancerMUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cellsMajor histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapyCD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.The immunomodulating roles of glycoproteins in epithelial ovarian cancer.Immunotherapy for gynaecological malignancies.Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.PILAR is a novel modulator of human T-cell expansion.The impact of T-cell immunity on ovarian cancer outcomes.Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunityProteasome regulation of ULBP1 transcription.CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytesExploiting natural killer group 2D receptors for CAR T-cell therapy.Naringenin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt's lymphoma cells.Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancerRegulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.The signature of liver cancer in immune cells DNA methylation.Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
P2860
Q21198791-B77A7083-5E97-409B-A053-64848DC8F819Q24814703-E24CD93B-1BB2-446D-9D3A-DE4F80223321Q26745898-50C81467-3D5E-4557-A1A1-578C245FD29FQ27014888-40BB361A-44FF-47BA-8A0E-6CE03D02B2A9Q27021878-23D826E5-2C40-460F-9C59-CD8D6B375D02Q27488697-16588B32-860F-4113-94E9-6A51B6F308FEQ33638962-E670EC45-2E0D-46D4-A0A2-3407014BD366Q33909404-69A58F3A-E69B-482F-8021-C987E10980F8Q34076429-ADD48984-8D74-4D89-AC60-7DC4DB953860Q34352531-6C6E976F-C25B-4DE5-A76E-95DC4266213AQ35077893-AF6CAF8B-25FF-4179-AA3C-CA0BA3E2C95DQ36239661-EDE8EE13-2360-4660-A344-58030033648AQ36520715-846D9777-434A-4B5C-A913-8518D82D6F16Q36810264-EFD1B000-C53B-4626-9171-C5A0A537F6F1Q36835181-0926B413-AE82-4313-8932-923253EA7F72Q37118142-D46B922F-8401-44FC-B281-8DD787FA1A68Q37169908-A35ADE8E-B49B-401B-8450-C136F70A8A1AQ37286656-A42A31C7-73C4-4289-A64F-6D547F6C8AFBQ37357720-AEBF4048-A65C-4AFC-92D4-DF90B323D52BQ37371532-9E21F578-426E-4374-AD84-28B02AC42080Q38266264-F690F3E1-E25F-427C-A03B-7352641DDB56Q38671184-47FD332A-4022-425E-BE55-172FC71C044EQ38861069-39076951-F099-43CF-B7C6-3C0CCF6556B2Q39525496-2DE496F4-CE54-4C51-9D57-F1C891151D1DQ39676621-B54B20A9-81CB-4DFB-86A1-314C99141131Q40108262-04142808-6705-4BE0-834F-428CE215BD2AQ42628431-41BFD309-70C7-4FA5-82FB-0A49CDEB0AEEQ48155719-1C08D851-4A66-445A-B587-688D9FA31EB6Q52590764-D51260B9-C030-4601-B34D-9A7DB6953CBCQ53453272-7960FD96-0E57-4DEB-A11D-57C97EE6D0A3
P2860
Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@ast
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@en
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@nl
type
label
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@ast
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@en
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@nl
prefLabel
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@ast
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@en
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@nl
P2093
P1433
P1476
Ovarian carcinoma expresses th ...... ion of CD28- antitumor T cells
@en
P2093
Bruce Levine
Craig B Thompson
Dionyssios Katsaros
Eugene Khang
Fabian Benencia
Jose R Conejo-Garcia
Kenneth A Frauwirth
Maria C Courreges
Phyllis A Gimotty
P304
P356
10.1158/0008-5472.CAN-03-2194
P407
P577
2004-03-01T00:00:00Z